ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) acknowledged the receipt of a Congressional letter and reaffirmed its commitment to discovering and developing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE